[1]
|
Yong, V.W., Wells, J., Giuliani, F., Casha, S., Power, C. and Metz, L.M. (2004) The promise of minocycline in neurology. The Lancet Neurology, 3, 744-751.
doi:10.1016/S1474-4422(04)00937-8
|
[2]
|
Conley, R.R. and Buchanan, R.V. (1997) Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin, 23, 663-674. doi:10.1093/schbul/23.4.663
|
[3]
|
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T. and Horiguchi, J. (2007) Possible antipsychotic effects of minocycline in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 304-307.
doi:10.1016/j.pnpbp.2006.08.013
|
[4]
|
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T. and Horiguchi, J. (2008) Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clinical Neuropharmacology, 31, 287-292.
|
[5]
|
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fenning, S., Treves, I. and Kron, S. (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in ealy-phase schizophrenia. Journal of Clinical Psychiatry, 71, 138-149.
doi:10.4088/JCP.08m04666yel
|
[6]
|
Chaudhry, I.B., Hallak, J., Husain, N., Minhas, F.A., Stirling, J., Richardson, P., Dursun, S., Dunn, G. and Deakin, B. (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomized double-blind placebo-controlled clinical trial in patients on standard treatment. Journal of Psychopharmacology (in press).
doi:10.1177/0269881112444941
|
[7]
|
Good, M.L. and Hussey, D.L. (2003) Minocycline: Stain devil? British Journal of Dermatology, 149, 237-239.
doi:10.1046/j.1365-2133.2003.05497.x
|
[8]
|
Colovic, M. and Caccia, S. (2003) Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. Journal of Chromatography B, 791, 337-343.
doi:10.1016/S1570-0232(03)00247-2
|
[9]
|
Bonelli, R.M., Heuberger, C. and Reisecker, F. (2003) Minocycline for Huntington’s disease: An open label study. Neurology, 60, 883-884.
doi:10.1212/01.WNL.0000049936.85487.7A
|
[10]
|
Shapiro, L.E., Knowles, S.R. and Shear, N.H. (1997) Comparative safety of tetracycline, minocycline, and doxycycline. Archives of Dermatology, 133, 1224-1230.
doi:10.1001/archderm.1997.03890460044005
|
[11]
|
Gottlieb, A. (1997) Safety of minocycline for acne. Lancet, 349, 374. doi:10.1016/S0140-6736(97)80006-2
|
[12]
|
Dommeguess, M.A., Plaisant, F., Vermey, C. and Gressens, O. (2003) Early microglial activation following neonatal excitoxic brain damage in mice: a potential target for neuroprotection. Neuroscience, 121, 619-628.
doi:10.1016/S0306-4522(03)00558-X
|
[13]
|
Yrjanheikki, J., Keinanen, R., Pellika, M., Hokfelt, T. and Hoistinaho, J. (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proceedings of the National Academy of Sciences, 95, 15769-15774. doi:10.1073/pnas.95.26.15769
|
[14]
|
Yrjanheikki, J.,Tikka, T., Keinanen, R., Goldstein, G., Chan, P.H. and Koistinaho, J. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proceedings of the National Academy of Sciences, 96, 13496-13500. doi:10.1073/pnas.96.23.13496
|
[15]
|
Tikka, T., Fiebich, B.L., Goldsteins, G., Keinnanen, R. and Koistinaho, J. (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. The Journal of Neuroscience, 21, 2580-2588.
|
[16]
|
Matsuki, S., Iuchi, Y., Ikeda, Y., Sasagawa, I., Tomita, Y. and Fujii, J. (2003) Suppression of cyctochrome c release and apoptosis in testes with heart stress by minocycline. Biochemical and Biophysical Research Communications, 312, 843-849. doi:10.1016/j.bbrc.2003.10.191
|
[17]
|
Tikka, T.M. and Koistinaho, J.E. (2001) Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. The Journal of Immunology, 166, 7527-7533.
|
[18]
|
Zhang, S.C., Goetz, B.D. and Duncan, I.D. (2003) Supression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors. Glia, 41, 191-198. doi:10.1002/glia.10172
|
[19]
|
Ekdahl, C.T., Claasen, J.H., Bonde, S., Kokaia, Z. and Lindvall, O. (2003) Inflammation is detrimental for neurogenesis in adult brain. Proceedings of the National Academy of Sciences, 100, 13632-13637.
doi:10.1073/pnas.2234031100
|
[20]
|
Stiring, D.P., Khodarahmi, K., Liu, J., et al. (2004) Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. The Journal of Neuroscience, 24, 2182-2190.
doi:10.1523/JNEUROSCI.5275-03.2004
|
[21]
|
Arvin, K.L., Han, B.H., Du, Y., Lin, S.Z., Paul, S.M. and Holzman, D.M. (2002) Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Annals of Neurology, 52, 54-61. doi:10.1002/ana.10242
|
[22]
|
Zhu, S., Stavrovskaya, I.G., Drozda, M., et al. (2002) Minocycline inhibits cytochrome c release and delayes progression of amyotrophic lateral sclerosis in mice. Nature, 417, 74-78. doi:10.1038/417074a
|
[23]
|
Wang, X., Zhu, S., Drozda, M., et al. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delayes mortality in a transgenic mouse model of Huntington disease, Nature Medicine, 6, 797-801. doi:10.1038/77528
|
[24]
|
Wang, J., Wei, Q., Wang, C.Y., Hill, W.D., Hess, D.C. and Dong, Z. (2004) Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. The Journal of Biological Chemistry, 279, 19948-19954.
doi:10.1074/jbc.M313629200
|
[25]
|
Gabler, W.L., Amith, J. and Tsukuda, N. (1992) Comparison of deoxycycline and a chemically modified tetracycline inhibition of leukocyte functions. Research Communications in Chemical Pathology & Pharmacology, 78, 151-160.
|
[26]
|
Amin, A.R., Attur, M.G., Thakker, G.D., et al. (1996) A novel mechanism of action of tetracyclines: Effect on nitric oxide synthases. Proceedings of the National Academy of Sciences, 93, 14014-14019.
doi:10.1073/pnas.93.24.14014
|
[27]
|
Young, V.W., Power, C., Forsyth, P. and Edwards, D.R. (2001) Metalloproteinases in biology and pathology of the nervous system. Nature Reviews Neuroscience, 2, 502-511. doi:10.1038/35081571
|
[28]
|
Golub, L.M., Ramamurthy, N., McNamara, T.F., et al. (1984) Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. Journal of Periodontal Research, 19, 651-655.
doi:10.1111/j.1600-0765.1984.tb01334.x
|
[29]
|
Paemen, L., Martens, E., Norga, K., et al. (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitiors. Biochemical Pharmacology, 52, 105-111.
doi:10.1016/0006-2952(96)00168-2
|
[30]
|
Power, C., Henry, S., Del Bigio, N.R., et al. (2003) Untracerebral hemorrhagew induces macrophage activation and matrix metalloproteinases. Annals of Neurology, 53, 731-742. doi:10.1002/ana.10553
|
[31]
|
Kloppenburg, M., Verweij, C.L., Miltenburg, A.M., et al. (1995) The influence of tetracyclines on T cell activation. Clinical and Experimental Immunology, 102, 635-641.
doi:10.1111/j.1365-2249.1995.tb03864.x
|
[32]
|
Kloppenburg, M., Brinkman, B.M., de Rooji-Dijk, N.H., et al., (1996) The tetracycline derivate minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrobial Agents and Chemotherapy, 40, 934- 940.
|
[33]
|
Hayashida, M., Miyaoka, T., Tsuchie, K., Yasuda, H., Wake, R., Nishida, A., Inagaki, T., Toga, T., Nagami, H., Oda, T. and Horiguchi, J. (2009) Hyperbilirubinemia-related behavioral and neuropathological changes in rats: A possible schizophrenia animal model. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 33, 581-588. doi:10.1016/j.pnpbp.2009.02.013
|
[34]
|
Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Wake, R., Ieda, M., Tsuchie, K., Taki, M., Ishihara, K., Tanra, A.J. and Horiguchi, J. (2012) Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: A possible schizophrenia animal model. Journal of Neuroinflammation, 9, 56.
doi:10.1186/1742-2094-9-56
|
[35]
|
Levkovitz, Y., Levi, U., Braw, Y. and Cohen, H. (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Research, 1154, 154-162.
|
[36]
|
Zhang, L., Shirayama, Y., Iyo, M. and Hashimoto, K. (2007) Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology, 32, 2004-2010.
doi:10.1038/sj.npp.1301313
|
[37]
|
Mizoguchi, H., Takuma, K., Fukakusa, A., Ito, Y., Nakatani, A., Ibi, D., Kim, H.C. and Yamada, K. (2007) Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology, 196, 233-241.
doi:10.1007/s00213-007-0955-0
|
[38]
|
Kay, S.R., Fiszbein, A. and Opler, L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13: 261-276.
|
[39]
|
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 1994; 4th Edition, American Psychiatric Press, Washington DC.
|
[40]
|
Weinberger, D.R. (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660-669.
doi:10.1001/archpsyc.1987.01800190080012
|
[41]
|
Waddington, J.L. (1993) Schizophrenia: Developmental neuroscience and pathology. Lancet, 341, 531-536.
doi:10.1016/0140-6736(93)90288-R
|
[42]
|
Arnold, S.E., Trojanowski, J.Q., Gur, R.E., Blackwell, P., Han, L.Y. and Choi, C. (1998) Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Archives of General Psychiatry, 55, 225-232.
|
[43]
|
Harrison, P.J. and Weinberger, D.R. (2005) Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Molecular Psychiatry, 10, 40-68. doi:10.1038/sj.mp.4001558
|
[44]
|
German, T.T., Tong, R.I., Gilmore, J.H., Lieberman, J.A. and Jarskog, L.F. (2004) Regulation of apoptosis by typical and atypical antipsychotics in rat frontal cortex. European Neuropsychopharmcology, 55, 214.
|
[45]
|
Ahuja, N. and Carroll, B.T. (2007) Possible anti-catatonic effects of minocycline in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 968-969.
doi:10.1016/j.pnpbp.2007.01.018
|
[46]
|
Kempermann, G., Krebs, J. and Fabel, K. (2008) The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Current Opinion in Psychiatry, 21, 290-295. doi:10.1097/YCO.0b013e3282fad375
|
[47]
|
Lei, G., Xia, Y. and Johnson, K.M. (2008) The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology, 33, 1343-1353. doi:10.1038/sj.npp.1301511
|
[48]
|
Csernansky, J.G. (2007) Neurodegeneration in schizophrenia: evidence from in vivo neuroimaging studies. Scientific World Journal, 7, 135-143.
doi:10.1100/tsw.2007.47
|
[49]
|
Lieberman, et al. (2007) Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectrums, 3, 1-13.
|